Feasibility and tolerability of 28 days intravaginal oxybutynin via the MedRing OAB system

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508692-36-00

Acronym

MedRing06

Enrollment

Registered

2024-02-05

Start date

2024-02-06

Completion date

2024-08-27

Last updated

2024-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026